KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Tax Provisions: 2009-2024

Historic Tax Provisions for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $676.0 million.

  • Teva Pharmaceutical Industries' Tax Provisions rose 210.14% to $214.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year decrease of 65.41%. This contributed to the annual value of $676.0 million for FY2024, which is 9757.14% up from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' Tax Provisions is $676.0 million, which was up 9,757.14% from -$7.0 million recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Tax Provisions registered a high of $676.0 million during FY2024, and its lowest value of -$643.0 million during FY2022.
  • In the last 3 years, Teva Pharmaceutical Industries' Tax Provisions had a median value of -$7.0 million in 2023 and averaged $8.7 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Tax Provisions slumped by 404.74% in 2022 and then soared by 9,757.14% in 2024.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Tax Provisions stood at -$168.0 million in 2020, then surged by 225.60% to $211.0 million in 2021, then tumbled by 404.74% to -$643.0 million in 2022, then skyrocketed by 98.91% to -$7.0 million in 2023, then soared by 9,757.14% to $676.0 million in 2024.